GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. (GTBP) on September 16, 2024. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC. The report addresses a change in the title and role of a key executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
Effective September 16, 2024, Dr. Jeffrey Miller ceased serving as the Registrant's Consulting Chief Medical Officer and Consulting Chief Scientific Officer. He commenced service as the Registrant's Consulting Senior Medical Director. This title change is commensurate with his role and was made in response to a request from the University of Minnesota, Dr. Miller's employer, to align with the University's policies regarding conflicts of interest. This adjustment is necessary given the impending conduct of the Phase I clinical trial of the Registrant's GTB-3650 compound at the University.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or general risk factors. The primary contingency noted is the alignment of Dr. Miller's role with University of Minnesota conflict of interest policies to facilitate the upcoming Phase I clinical trial for the GTB-3650 compound.
Key Facts for Investor Verification
- Dr. Jeffrey Miller's title changed from Consulting Chief Medical Officer/Chief Scientific Officer to Consulting Senior Medical Director effective September 16, 2024.
- The change was driven by conflict of interest policies at the University of Minnesota.
- The adjustment supports the upcoming Phase I clinical trial of the GTB-3650 compound at the University of Minnesota.
- No financial data or operational metrics are disclosed in this specific filing.